Organon & Co. (OGN)
(Delayed Data from NYSE)
$20.29 USD
+0.13 (0.64%)
Updated Sep 12, 2024 04:00 PM ET
After-Market: $20.31 +0.02 (0.10%) 7:58 PM ET
4-Sell of 5 4
A Value F Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$20.29 USD
+0.13 (0.64%)
Updated Sep 12, 2024 04:00 PM ET
After-Market: $20.31 +0.02 (0.10%) 7:58 PM ET
4-Sell of 5 4
A Value F Growth A Momentum B VGM
Zacks News
Is SPDR Portfolio S&P 500 High Dividend ETF (SPYD) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for SPYD
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RYH)?
by Zacks Equity Research
Sector ETF report for RYH
Is Invesco S&P 500 Equal Weight Health Care ETF (RYH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RYH
Organon (OGN) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Organon (OGN) delivered earnings and revenue surprises of 25.95% and 3.88%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Organon (OGN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Organon (OGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should WisdomTree U.S. MidCap ETF (EZM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for EZM
Why Organon (OGN) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Organon (OGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Is WisdomTree U.S. MidCap ETF (EZM) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for EZM
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
by Zacks Equity Research
Sector ETF report for XPH
Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XPH
Will Organon (OGN) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Organon (OGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
by Zacks Equity Research
Sector ETF report for XPH
Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XPH
Why Organon (OGN) Could Beat Earnings Estimates Again
by Zacks Equity Research
Organon (OGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
by Zacks Equity Research
Sector ETF report for XPH
Is SPDRSP PHARMA (XPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XPH
Organon's (OGN) Earnings & Revenues Surpass Estimates in Q3
by Zacks Equity Research
Organon's (OGN) earnings and revenues trump estimates in the third quarter of 2021. Shares down in pre-market trading.
Organon (OGN) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Organon (OGN) is set to provide updates on its earnings and revenues when it reports third-quarter 2021 results.
Organon's (OGN) Q2 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Organon's (OGN) earnings and revenues beat estimates in the second quarter of 2021. Stock up in pre-market trading.
Merck (MRK) Q2 Earnings Miss, Sales Rebound, Stock Slips
by Zacks Equity Research
Merck (MRK) misses Q2 estimates for earnings but beats the same for sales. Stock down in pre-market.
Merck (MRK) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on the sales numbers of Merck's (MRK) blockbuster oncology medicine, Keytruda.